INDUSTRIAL IMPACT

Lummus and Synthos Advance Bio-Butadiene Technology Development to Produce Sustainable Rubber

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project.

Given the confidence in the technology and the strong market demand for renewable materials, Synthos has committed to building a plant with a capacity of 40,000 metric tons of bio-butadiene per year – twice as much as the companies had originally planned. In addition to the plant capacity expansion, Synthos has confirmed that it will license BASF's butadiene extraction technology from Lummus and leverage Lummus' digitalization capabilities for operational efficiency and reliability.

"Since Lummus began collaborating with Synthos last year, it has become evident that this technology has the potential to be the new standard in our industry due to its renewable sourcing, production efficiency and low carbon footprint. The petrochemical industry is quickly adjusting to ambitious sustainability requirements, and at Lummus we continue to lead this change on multiple fronts. The commercialization with Synthos of this bio-technology for more sustainable rubber products is one of several sustainable process solutions that are making a positive impact."

Leon de Bruyn, President and Chief Executive Officer of Lummus Technology
 

"Synthos is making great strides in developing a synthetic rubber product portfolio with a significantly reduced environmental footprint. Entering the next phase of our collaboration with Lummus is another step toward our commitment to help our customers achieve their performance and sustainability goals," said Matteo Marchisio, Synthetic Rubber Business Unit Director, Synthos. "We believe the availability of sustainable synthetic rubber made from bio-butadiene will play an important role in the industry's ability to meet the demands of modern mobility, and we are proud to partner with Lummus Technology to lead the way."

Synthos is a global leader in the development and production of synthetic rubber for tires and technical rubber goods and is committed to providing its customers with high-performance material solutions with a lower environmental footprint.

In 2021, Green Circle and Synthos announced that they will collaborate on the development and commercialization of bio-butadiene derived from bio-ethanol to enable the production of value-added, more sustainable synthetic rubber.

A subsidiary of Lummus, Green Circle is a leader in commercializing and developing breakthrough solutions to address the key pillars of the energy transition, including end-of-life waste plastics recycling, production of bio derived sustainable chemicals, and decarbonization strategies for existing and new assets.

About Lummus Technology
Lummus Technology is the global leader in developing process technologies that make modern life possible and focus on a more sustainable, low carbon future. Lummus is a master licensor of clean energy, petrochemical, refining, gas processing and renewable technologies, and a supplier of catalysts, proprietary equipment, digitalization and related lifecycle services to customers worldwide. 

About Synthos
Synthos S.A. is a chemical producer and a major player in the global synthetic rubber market. Synthos S.A. Capital Group's business includes the production and sales of chemical products used as raw materials and intermediates in a wide range of industries, particularly in the tire industry, the construction industry and the packaging industry. 

Spotlight

Although the concept of biotechnology generally brings to mind genetic engineering, it can be conceived of very broadly. Any use of biological organisms or processes in industrial, medical, agricultural and environmental engineering.

Spotlight

Although the concept of biotechnology generally brings to mind genetic engineering, it can be conceived of very broadly. Any use of biological organisms or processes in industrial, medical, agricultural and environmental engineering.

Related News

MEDICAL

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Willow Biosciences | June 01, 2022

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceutical products. The Counterparty is partnered with a large-cap, multi-national healthcare company. This is a significant step forward in the evolution of Willow's business ,This new partnership highlights the capabilities of our scientific team, and demonstrates to our stakeholders the wide array of opportunities accessible to Willow's comprehensive FutureGrownTM technology platform. As Willow continues to expand its capabilities and add new partnerships, Willow is on a path to becoming the premier name in biobased manufacturing." Trevor Peters, Willow's President and Chief Executive Officer. The project consists of research & development and commercialization phases, with revenue coming from both research fees and milestone payments. Following commercialization, Willow anticipates an on-going revenue stream from license payments. About Willow Biosciences Inc. Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

Read More

INDUSTRIAL IMPACT

BeiGene Announces Launch of Bioisland Innovation Center

BeiGene | December 27, 2021

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced the official launch of the BeiGene Bioisland Innovation Center in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world. “Over a decade ago, we started BeiGene’s journey by following the science and have grown to be a global biotechnology company with capabilities across the full value chain. With the BIC, we are supporting entrepreneurs with similar purpose and vision of delivering innovation that will benefit more patients worldwide. We expect the center will also contribute to our innovation pipeline,” John V. Oyler, Co-Founder, Chairman and CEO of BeiGene “Science and innovation are BeiGene’s core strengths. We are committed to supporting entrepreneurs incubate bold, new ideas into impactful programs that will create value for patients and benefit patients globally,” added Xiaodong Wang, M.D., Co-Founder of BeiGene, Chairman of the Company’s Scientific Advisory Committee. “With our scientific research, unique clinical development capabilities, and footprint, BeiGene is well positioned to explore new paths of innovation and support new talents in the booming biotechnology hub of Guangzhou’s Greater Bay Area.” Innovator-Centric Incubator to Accelerate Growth and Possibilities The BIC is located in the Guangdong-Hong Kong-Macau Greater Bay Area, an emerging global biotechnology hub, and will feature a comprehensive research infrastructure and professional management team. The incubator will be equipped with state-of-the-art laboratory infrastructure and comprehensive research capabilities that enable scientists and entrepreneurs to get their ideas off the ground. In addition, scientists and entrepreneurs at the BIC will have potential access to support from BeiGene on full industry value chain integration. The comprehensive, advanced technology platform at the BIC will allow innovators more autonomy in development, and integrated services to position them for growth. “The BIC is focused on cultivating entrepreneurship for new biotech companies with a passion for transformational medicines, diagnostics and medical devices that can help address unmet needs, and advancing breakthrough innovations from early discovery to being accessed by patients all over the world,” said Jonathan Liu, Chief Executive of Bioisland Initiative and Chairman of the Board of BeiGene Biologics Co., Ltd. Dr. H. Fai Poon. CEO of Zhongshan Quacell Biotechnology Co., Ltd., which is part of the innovation center, commented, "We share the same beliefs of the model and concept of the BeiGene Bioisland Innovation Center. This kind of international collaboration not only accelerates technical innovation for small and medium-sized enterprises, but also provides suitable platforms and resources to commercialize these innovations. For Quacell, which also has the 'innovative DNA', to be part of the BIC provides the opportunity to communicate and cooperate with many innovative companies in different fields around the world. We look forward to creating a common path for each other's future research and development. And we believe that this path leads to infinite possibilities to upgrade and even revolutionize the industry." About BeiGene BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 8,000 colleagues across five continents.

Read More

CELL AND GENE THERAPY

Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Superstring. Existing investors Boxer Capital, BVF Partners, L.P., Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, a Gilead Company, Stork Capital, Wedbush Healthcare Partners and an undisclosed leading global investment firm, also participated. In connection with the financing, Frank Yu, Founder, CEO and CIO of Ally Bridge Group, joined the Shoreline Board of Directors. "We are proud of Shoreline's tremendous progress over the past year, including next generation, more persistent and more effective iPSC-derived NK cells, enhancing our core technologies, advancing our preclinical programs, establishing transformative and validating partnerships with Kite and BeiGene, creating smart manufacturing methods, and attracting exceptional talent to support our next phase of development and growthWith this financing and our corporate partnerships, Shoreline has now more than $300 million to continue building our pipeline of safe, effective and affordable cellular immunotherapies for both solid tumors and hematologic malignancies." Kleanthis G. Xanthopoulos, Ph.D., Shoreline's co-founder, Chairman and Chief Executive Officer "Having invested in – and followed closely for several years -- the iPSC-derived NK cells-based therapeutics field which has made highly encouraging progress in the clinic, we are convinced of the true differentiation demonstrated by the Shoreline technology platform. Ally Bridge Group, a leading investor in best-in-class cell therapy companies from oncology to autoimmune diseases, expects Shoreline to be a new category leader," said Frank Yu, Founder, CEO and CIO of Ally Bridge Group. The proceeds from the financing will allow Shoreline to continue the advancement of its proprietary iPSC platform focused on developing next generation natural killer (NK) cell and macrophage-cell therapies, create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs) as well as switchable CAR-NK cell engagers and macrophage-specific CARs to treat blood cancers, solid tumors, and other health conditions. With the close of this financing, Shoreline is well-capitalized with greater than $300 million, including committed partnership R&D funding, to execute on its goals and advance its pipeline. About Shoreline Biosciences Shoreline is dedicated to creating next-generation cellular immunotherapies for cancer that overcome the current limitations of first-generation cell therapy products. Shoreline is building a pipeline of natural killer cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Shoreline has strategic partnerships with Kite, a Gilead Company, and BeiGene, a global biotechnology company, Contract Development and Manufacturing Organization partnerships with well-established organizations, and is supported by high-quality investors. Shoreline Biosciences is headquartered in San Diego, CA.

Read More